Results 181 to 190 of about 45,681 (215)

Activity of cefiderocol against <i>Pseudomonas aeruginosa</i> from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. [PDF]

Microbiol Spectr
Kimbrough JH, Karr MH, Nguyen ST, DeJonge BLM, Longshaw C, Takemura M, Yamano Y, Castanheira M, Mendes RE.   +8 more
europepmc   +1 more source

Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. [PDF]

Future Microbiol
McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS.   +4 more
europepmc   +1 more source

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study. [PDF]

J Antimicrob Chemother
O'Jeanson A, Nielsen EI, Friberg LE.
europepmc   +1 more source

ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten. [PDF]

Antimicrob Agents Chemother
Jacobs MR, Good CE, Abdelhamed AM, Mack AR, Bethel CR, Marshall SH, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.   +16 more
europepmc   +1 more source

Amphiphilic nebramine analogs synergize with β-lactam/β-lactamase inhibitor combinations, including cefepime-taniborbactam and meropenem-xeruborbactam against metallo-β-lactamase-carrying <i>Pseudomonas aeruginosa</i>. [PDF]

RSC Med Chem
Lozeau C, Ramirez D, Ramirez D, Kumar G, Arora R, Zhanel G, Arthur G, Schweizer F.   +7 more
europepmc   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020-2022). [PDF]

BMC Pulm Med
Sader HS, Mendes RE, Ryan Arends SJ, Doyle TB, Castanheira M.   +4 more
europepmc   +1 more source

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series. [PDF]

Eur J Clin Microbiol Infect Dis
Boattini M, Bianco G, Comini S, Costa C, Gaibani P.   +4 more
europepmc   +1 more source